A correlative blood assay to monitor patients at risk for chemotherapy-induced peripheral neuropathy
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Results

Introduction

Objective

Chemotherapy-induced peripheral neuropathy
(CIPN) is a disabling side effect of platinum-based
chemotherapies like cis-, oxali- and carboplatin.
These therapies cause bursts of reactive oxygen
species (ROS), which can trigger structural changes
in peripheral nerves including neuronopathy,
axonopathy and/or myelinopathy. There is no
effective CIPN prevention strategy and medications
to alleviate neuropathy often lack efficacy and/or
have unacceptable side-effects.

Glutathione, an antioxidant, plays an important
role in red-ox homeostasis and the recycling of
glutathione can be determined by the ChemoTox
assay.4 The aim of this study was to determine if
ChemoTox can provide clinicians with a blood assay
to quantitate platinum-induced neuropathy.

Background
The “stocking and glove” distribution of
neuropathy is primarily due to the vulnerability of
long nerves in the peripheral nervous system. A
meta-analysis of 31 CIPN studies involving 4,179
patients indicated CIPN in 48% of patients. Within
the first month of completing chemotherapy, the
prevalence of CIPN was 68.1%; after 6 months of
completing chemotherapy, the prevalence of CIPN
decreased to 30.0%.1 A separate study indicated
colon cancer patients who received oxaliplatin-based
adjuvant chemotherapy had numbness or tingling of
hands and feet up to 6 years from starting
treatment.2 Due to the high frequency of neuropathy,
there is a need for a test that can help clinicians
better guide therapy and prevent this detrimental
outcome.3

• 72.2% reported neuropathy during
chemotherapy and 35.6% were recognized as
high risk patients for progressive CIPN. These
outcomes, despite the small cohort size, are
representative of larger studies.
• Patients LH12-015, LH12-018 and LH12-039
display trends that initially show decreased
glutathione recycling capacities and remain low
over time. This correlation detects a patient
population that can be addressed earlier as to
the direction of treatment.
• Patients LH12-026, LH12-027 and LH12-036
illustrate a patient population that initially display
adequate glutathione recycling capacity.
However, the inability to maintain turnover
during extended treatment cycles identifies the
inverse correlation as a trend of concern.
• Low glutathione recycling also has a corollary to
an increased risk for chemotherapy induced
nausea and vomiting (CINV). Among the
patients shown in results, 5/6 patients reported
some level of nausea, and 4/6 reported
moderate to severe delayed nausea.4

Materials & Methods
The cohort of cancer patients are from the
Lankenau Medical Center outside of Philadelphia, PA.
The hospital sees ~1,100 cancer patients per year.
Colorectal patients constitute 14.7% while 10.4% are
lung cancer patients. Of the patients enrolled in this
study, 84.4% are Caucasian, 14.0% are AfricanAmerican and 1.6% are Asian.
Blood drawn from consented and chemotherapy
naïve patients (N= 59) were tested for glutathione
recycling capacity and normalized to total red cell
numbers. Patients reported neuropathy using the
Rotterdam Symptom Check List. Patient’s glutathione
recycling capacities were correlated to self-reported
neuropathy.
Characteristics
Number of patients

59

•

64 (24 – 91)

Median age (range)
Female

Future Directions

Number of
patients

Patients (%)

47.5

28

Primary Tumor
Colorectal

55.9

33

Lung

44.0

26

Chemotherapy treatments
59
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Discussion

52.7

35

Oxaliplatin

52.5

31

Carboplatin

38.9

23

Cisplatin

8.47

5

42 of 59 patients stated they experienced
neuropathy during chemotherapy. 21 high risk
patients were identified as those who reported
experiencing neuropathy as a “2”, or “quite a bit” on
the Rotterdam Checklist. 19 of the 21 patients
experienced increasing neuropathy within their first
5 treatments. Select correlates above are patientreported neuropathy (0-3) in blue, and ChemoTox
quantities (ng / ml plasma and 106 RBC) in red.

•

Taxane therapies, another culprit for causing
CIPN via ROS, is a target population for future
studies of ChemoTox efficacy.
Platinum therapy as a treatment for breast
cancer should be explored to see if systemic
ROS provides a similar pattern to that of patients
with lung and colon cancer.
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